The Pharma Data

MAY 13, 2021

Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing. . Sanofi’s Libtayo shows positive Phase III results in advanced cervical cancer ( Pharmafile ). A Third Rock-backed player charts a new course against transcription factors. . In Focus: US.

FDA Approval 52

FDA Approval Vaccination Vaccine Drugs 52

XTalks

OCTOBER 15, 2021

Tedros Adhanom Ghebreyesus honored Henrietta Lacks with a WHO Director-General’s award, “recognizing the world-changing legacy of this Black American woman who died of cervical cancer, 70 years ago, on 4 October, 1951,” said the health agency in a news release. Henrietta Lacks died at the age of 31.

Vaccination 105

Vaccination Vaccine Gene Mapping Doctors 105

XTalks

FEBRUARY 13, 2024

It combines deep-learning-based artificial intelligence (AI) with advanced volumetric imaging technology to help in the diagnosis of pre-cancerous lesions and cervical cancer cells. Detecting and identifying cervical cancer in the earliest stages is critical to effective prevention and treatment.

Development 69

Development FDA Approval Marketing Drugs 69

Triage Cancer

OCTOBER 29, 2020

In Houston, at least a dozen patients have told fertility specialist Dr. Rashmi Kudesia they’re having irregular menstrual cycles, changes in cervical discharge and breast tenderness, despite normal hormone levels. As the immune system acts up, some people can even develop new allergic reactions, Harkness said.

Hormones 75

Hormones Doctors Doctor Pharmacy 75

Drug Discovery World

APRIL 11, 2024

The Program Committee Chairs commented: “It has been an educational, enlightening, and inspiring week of captivating cancer science and research. Thanks, too, to the members of the AACR for their support of this organisation’s meaningful mission to prevent and cure all cancers. And thanks to the city of San Diego for its hospitality.”

HR 52

HR Antibody In-Vitro DNA 52

XTalks

FEBRUARY 26, 2021

Fundamentals in Cancer Research: Henrietta Lacks and HeLa Cells. Despite being a cancer cell line, it is used in many different biomedical research areas owing to the cells’ ability to rapidly proliferate. The cell line was sourced from cervical cancer cells from a Black woman named Henrietta Lacks.

Scientist 69

Scientist Research Genetics Cosmetics 69

pharmaphorum

MARCH 25, 2022

AstraZeneca’s hopes of developing its PD-L1 inhibitor Imfinzi for cervical cancer have been hit by a failed phase 3 trial of the drug alongside chemotherapy as a first-line treatment for women with locally-advanced tumours. The post AstraZeneca’s Imfinzi fails in cervical cancer bid appeared first on.

Trials 95

Trials Sales Drugs Medicine 95

Scienmag

MAY 16, 2022

A recent database analysis reveals that in recent years, sexual minority individuals—those whose sexual orientation differs from societal norms—were less likely to have undergone cervical cancer screening tests than heterosexual counterparts, with Hispanic sexual minority individuals having the lowest screening rates.

75

75

pharmaphorum

MAY 9, 2022

vaccine to treatment with Roche’s cancer immunotherapy Tecentriq resulted in disease control in two-thirds of patients with advanced cervical cancer. NEO , its individualised cancer vaccine partnered with Roche. The post Nykode vaccine shows its worth in cervical cancer trial appeared first on.

Vaccination 62

Vaccination Vaccine Trials DNA 62

Scienmag

MARCH 18, 2022

A Phase I/Ib trial conducted by the National Cancer Institute (NCI) National Clinical Trials Network (NCTN) group NRG Oncology, NRG-GY017, concluded that the addition of the immunotherapy drug atezolizumab prior to and concurrently given with chemoradiation (CRT) treatment was safe for women with node-positive, locally advanced cervical cancer.

Trials 62

Trials Clinical Trials Clinical Trials Drugs 62

pharmaphorum

JUNE 23, 2021

Merck & Co’s Keytruda has become the first checkpoint inhibitor to help patients with advanced cervical cancer live longer when used as alongside standard first-line drugs. The five year survival rate for stage 3 (locally spread) and 4 (metastatic) cervical cancer is around 40% and 15%, respectively.

Trials 65

Trials Drugs Licensing Licensing 65

pharmaphorum

SEPTEMBER 21, 2021

Antibody-drug conjugate (ADC) specialist Seagen has claimed its fourth product approval in the US, getting the nod from the FDA for Tivdak as a second-line monotherapy for recurrent or metastatic cervical cancer. Cervical cancer is one of the leading causes of death for women globally.

Antibody 52

Antibody Pharma Companies Trials Drugs 52

Triage Cancer

JANUARY 28, 2021

2021 has brought a new presidential administration, a new Congress, and new state elected officials. So, we are likely to see many new proposed laws and regulations that may impact the cancer community. Triage Cancer remains committed to bringing you the news that might impact the cancer community.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Doctors 98

pharmaphorum

MARCH 15, 2021

Sanofi and Regeneron’s checkpoint inhibitor Libtayo has become the first immunotherapy to improve survival when used as a second-line therapy in cervical cancer, setting up regulatory filings later this year. The trial enrolled patients with advanced cervical cancer regardless of PD-L1 status.

Trials 52

Trials Sales Vaccination Vaccine 52

The Pharma Data

OCTOBER 18, 2020

The purpose of this exploratory Phase 1b/2 trial was to evaluate the safety and efficacy of the combination of TG4001 and an immune checkpoint inhibitor in a heterogeneous group of patients with aggressive, recurrent and/or metastatic HPV16-positive cancer. 19, 2020 05:30 UTC. Christophe Le Tourneau, M.D.,

Containment 40

Containment Trials Vaccination Vaccine 40

XTalks

AUGUST 9, 2022

The new RTF-EXPAR testing platform is also being adapted for the detection of new variants of SARS-CoV-2 as well as other viruses, such as human papillomavirus (HPV) which cause cancers like cervical cancer.

Licensing 98

Licensing Licensing DNA RNA 98

The Pharma Data

OCTOBER 26, 2020

The purpose of this exploratory Phase 1b/2 trial was to evaluate the safety and efficacy of the combination of TG4001 and an immune checkpoint inhibitor in a heterogeneous group of patients with aggressive, recurrent and/or metastatic HPV16-positive cancers. 27, 2020 06:30 UTC. – .

Vaccination 52

Vaccination Vaccine Trials Containment 52

The Pharma Data

JULY 8, 2021

This approval is great news for these patients and further demonstrates Merck’s commitment to the skin cancer community. This expanded indication reinforces the role of KEYTRUDA in this cancer type, which is the second most common form of non-melanoma skin cancer.”. Non-Small Cell Lung Cancer.

FDA Approval 52

FDA Approval Containment Trials Genome 52

XTalks

JANUARY 9, 2024

Cervical Cancer Awareness Month 2024, also known globally as world cervical cancer awareness month, is observed for the entire month of January. This significant healthcare event aims to raise awareness and advocate for the elimination of cervical cancer.

Vaccination 64

Vaccination Vaccine FDA Approval Clinical Trials 64

XTalks

MARCH 1, 2024

International HPV Awareness Day 2024 falls on March 4 and plays an important role in increasing awareness about human papillomavirus (HPV), a virus linked to many types of cancers and other diseases. The types of HPV that might cause cancer, particularly HPV 16 and HPV 18, are high-risk HPV.

Vaccination 52

Vaccination Vaccine Life Science FDA Approval 52

Pharmaceutical Technology

JUNE 20, 2023

However, some strains of the virus can cause cervical cancer and, less frequently, cancers of the vagina, vulva, penis, and anus. This is excellent news for young people.” Currently, the NHS uses Gardasil 9 developed by MSD , which is also known as Merck in US and Canada.

Vaccination 264

Vaccination Vaccine Development 264

pharmaphorum

FEBRUARY 11, 2021

Seagen and Genmab have announced they have filed their antibody-drug conjugate tisotumab vedotin with the FDA for patients with recurrent or metastatic cervical cancer. The antibody is designed to seek out a receptor called ‘tissue factor’ – present at high levels on the surface of many cancer cells and linked with worse survival.

Drugs 104

Drugs Antibody Trials Research 104

XTalks

NOVEMBER 9, 2023

Abbott’s molecular human papillomavirus (HPV) screening solution has received approval from the US Food and Drug Administration (FDA) for detecting high-risk HPV infections and as a primary cervical cancer screening tool. The HPV test is an addition to Abbott’s Alinity m diagnostic assay family.

FDA Approval 64

FDA Approval HR Genotype Life Science 64

pharmaphorum

NOVEMBER 23, 2022

Regeneron has announced that the European Commission (EC) has approved Libtayo (cemiplimab) as a monotherapy for the treatment of adult patients with second-line recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy. The results were published in the New England Journal of Medicine.

Trials 57

Trials Antibody Vaccination Vaccine 57

The Pharma Data

FEBRUARY 4, 2021

At the virtual American Society of Hematology Annual Meeting and Exposition (ASH), AbbVie presented data from nearly 40 abstracts on 8 investigational and approved products across 11 cancer types, including 10 oral presentations. and by AbbVie outside of the U.S. Forward-Looking Statements.

Botox 52

Botox Production Sales Cosmetics 52